in Health care
Setback: Merck, Eisai to stop late-stage study of Keytruda plus Lenvima for metastatic melanoma
Rahway: Merck & Co Inc and Eisai Co Ltd said on Friday they were discontinuing a late-stage study of Keytruda plus Lenvima for the treatment of adults with unresectable or metastatic melanoma, as the trial did not show improvement in overall survival. The decision to discontinue the trial was based on the recommendation of an independent data […] More
